Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277690 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
A Phase 3 study of Endogenous Cushing's Syndrome, sponsored by Cortendo AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT03277690 is a Phase 3 study of Endogenous Cushing's Syndrome that has completed, run by Cortendo AB. The registered enrollment target is 84 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT03277690, a Phase 3 study of Endogenous Cushing's Syndrome, has completed, sponsored by Cortendo AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration study in subjects with endogenous Cushing's Syndrome (CS) previously treated with single-arm, open-label levoketoconazole that will assess efficacy, safety, tolerability, and pharmacokinetics of levoketoconazole.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Levoketoconazole
Study Locations (20)
Other
- Alexandovska University Hospital, Clinic of Endocrinology & Metabolic Diseases - Sofia
- University Multiprofile Hospital for Active Treatment "Aleksandrovska" EAD Clinic of Endocrinology and Metabolic Diseases - Sofia
- University Specialized Hospital for Active Treatment in Endocrinology (USHATE) I Klinika - Sofia
- Rigshospitalet, Copenhagen University Hospital, Endocrinology Department - Copenhagen
- Evangelismos Athens General Hospital, Department of Endocrinology - Athens
- General Hospital of Athens 'G. Gennimatas', Department of Endocrinology-Diabetes Centre - Athens
California
- Keck Medical Center University of Southern California HCII, Internal Medicine - Keck Hospital - Los Angeles
- Cedars-Sinai Medical Center, Cedars-Sinai Pituitary Center - Los Angeles
- UCLA School of Medicine, Medicine/Endocrinology Department - Los Angeles
New York
- Columbia University, College of P&S Medicine/Neuro-endocrine Unit - New York
- Memorial Sloan Kettering Cancer Center, Endocrinology - New York
Florida
- The Center for Diabetes and Endocrine Care - Fort Lauderdale
Georgia
- Emory University, Neurosurgery - Atlanta
Illinois
- Northwestern University, Medicine - Endocrinology - Chicago
Maryland
- Johns Hopkins University, Endocrinology Department - Baltimore
Michigan
- University of Michigan, Comprehensive Endocrine Research, Internal Medicine - MEND - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03277690
The ClinicalTrials.gov registry entry for NCT03277690 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cortendo AB, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endogenous Cushing's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03277690 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT03277690 about?
NCT03277690 is a clinical study titled "A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.". This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration study in subjects with endogenous Cushing's Syndrome (CS) previously treated with single-arm, open-label levoketoconazole that will assess efficacy, safety, tolerability, and pharmacokinetics of levoketoconazole...
What is the current status of trial NCT03277690?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2017-09-26. Estimated completion is 2020-08-31.
What conditions does trial NCT03277690 study?
This clinical trial studies the following conditions: Endogenous Cushing's Syndrome.
What interventions are being tested in trial NCT03277690?
The interventions under investigation include: Placebo (DRUG), Levoketoconazole (DRUG).
Who is sponsoring clinical trial NCT03277690?
This trial is sponsored by Cortendo AB, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03277690 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endogenous Cushing's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.